Quantum Health Sets New Standard for Transparency and Value in Healthcare Navigation Amid Growing Employer Concerns About Escalating Costs
DUBLIN, Ohio--(BUSINESS WIRE)-- Quantum Health, the creator of healthcare navigation, today announced the launch of its new comprehensive intervention and value reporting capability, Action to Impact, which proves – at the member level – how its healthcare navigation model reduces costs, improves outcomes and enhances employee experience. Powered by a dynamic AI engine and 25 years of proprietary data, Action to Impact provides transparent, actionable evidence, connecting specific navigation actions to quantifiable results.
"We don't just show engagement metrics — we connect employers to real savings, better care and improved member experiences.' - Chris Reed, Director of Value Creation, Quantum Health
Share
This launch comes at a time when self-insured employers are demanding more from their healthcare and benefits investments. According to the newly released State of Healthcare Survey 2025: The Transformative Power of Trust in Healthcare by Arizent and Employee Benefit News (EBN), sponsored by Quantum Health, 79% of employers identified company cost as the top concern they are focused on addressing in their latest annual benefits cycle.
While these value-driving interactions have long been part of Quantum's model, Action to Impact offers a new way to package and share insights with clients and consultants, while giving internal teams real-time feedback for continuous improvement. The solution connects every touchpoint, from navigation and steerage to clinical support, continuously optimizing member and provider experiences to improve clinical, financial and satisfaction outcomes. By transforming traditional ROI into specific, actionable insights, Quantum Health proves the value of its interventions for each client.
"Proving our ability to drive better outcomes at a lower cost has never been more essential. Today's clients expect more than anecdotes — they demand data-driven answers to their most pressing questions,' said Chris Reed, Director of Value Creation at Quantum Health. 'Employers want specifics: What actions were taken? What actually worked? With Action to Impact, Quantum Health delivers those answers through advanced analytics that quantify how navigation interventions reduce costs and improve outcomes."
At the heart of Quantum Health's approach is its proprietary Real-Time Intercept® (RTI) platform, which enables member engagement an average of 110 days before the first claim — often before costs or complexity escalate. These early 'value moments' offer critical opportunities to influence care decisions and outcomes, allowing Quantum Health clients to achieve better health and financial results through meaningful, proactive engagement. These results are independently validated by MorningStar Actuarial Consulting, whose study of 2018-2022 claims data finds that Quantum Health's navigation and care coordination solution produces substantial and steadily accumulating ROI.
Why This Matters —
Self-insured employers are under pressure to do more with less – and prove it. As HR teams seek to optimize every dollar spent, Quantum Health's Action to Impact analytics deliver the insight needed to rise to that challenge.
"Trust is a key part of the value equation for employees,' said Kerry Gross, Director of Research Intelligence at Arizent. 'Those who trust that the entities supporting their care have their best interests in mind are more likely to get preventive primary care and more likely to be satisfied with their overall wellness offerings."
Employers are turning to data to guide their healthcare decisions. The EBN State of Healthcare survey indicates that utilization data (88%) and insurance claims data (84%) are reported as the most trusted sources. Meanwhile, 53% of employers say they are confident their navigation partner can demonstrate how member engagement translates into cost savings. Still, just under half are only somewhat or slightly confident that engagement and cost savings data is being clearly tied together.
"We don't just show engagement metrics — we connect them to real savings, better care and improved member experiences,' added Reed. 'Our enhanced reporting pinpoints the most complex journeys, identifies where the greatest value is created, and outlines next steps to maximize results. As our dataset matures, insights become even more predictive, helping clients stay ahead of emerging challenges."
To explore the full results of the 2025 State of Healthcare study, visit benefitnews.com.
About Employee Benefit News Employee Benefit News (EBN) is the leading media resource for decision-makers in employee benefits, HR, and workplace culture. EBN provides critical insights to help business leaders navigate shifting industry dynamics, reduce care costs, improve retirement plans, and build diverse, high-performing workforces. Learn more at www.benefitnews.com.
About Arizent Research Arizent delivers actionable insights through full-service research solutions powered by first-party data, expert perspectives, and engaged professional communities. Its portfolio includes trusted brands across financial services and professional sectors, such as American Banker, Financial Planning, Accounting Today, and Employee Benefit News. For more, visit www.arizent.com.
About Quantum Health Celebrating 25 years of innovation, Quantum Health is a leading consumer healthcare navigation and care coordination company. Its Real-Time Intercept® platform identifies early intervention opportunities to improve engagement, outcomes, and cost efficiency. Based in Dublin, Ohio, Quantum Health has earned national recognition for growth and workplace culture, including honors from FORTUNE, Inc. 5000, and the Women Presidents' Organization.
To learn more, visit www.Quantum-Health.com and connect on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen Torley, President and CEO of Halozyme. "The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future." The Russell 1000® is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the future execution of Halozyme's strategy and delivery of future sustainable growth and profitability, the durability of Halozyme's top and bottom line growth, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in the execution of Halozyme's strategy and unexpected future financial results and top and bottom line growth,. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney View original content to download multimedia: SOURCE Halozyme Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Strongest Appetite Suppressant Over the Counter Now Available in USA - PhenQ Medically Accredited Craving Control Supplement OTC
Clinicians' Choice Appetite Suppressant, PhenQ: Medically Accredited by 800 Professionals and Now Launched in the USA Without Prescription Phenq New York City, NY, June 30, 2025 (GLOBE NEWSWIRE) -- For Americans seeking the most effective, safe, and convenient way to control food cravings and promote weight loss, a breakthrough is here. PhenQ, the strongest appetite suppressant over the counter (OTC), has officially launched in the United States and worldwide—earning the rare and coveted 'clinicians' choice' status after being medically accredited by over 800 medical professionals. For men and women looking to lose weight, manage appetite, and improve overall health without the risks of prescription appetite suppressants or weight loss drugs, PhenQ is the OTC appetite suppressant the world has been waiting for. Product Launch: A New Era for Clinician-Backed OTC Appetite Suppressants PhenQ's arrival marks a turning point in the world of weight loss supplements. For decades, Americans have struggled to find effective appetite suppressant pills that are both safe and available without a prescription. Prescription appetite suppressants and weight loss drugs often require doctor supervision, can lead to high blood pressure, and may not be suitable for those with a higher body mass index or specific health concerns. Now, with PhenQ, users can experience the best appetite suppressant over the counter, with a formula that has been medically accredited, approved, and recommended by over 800 clinicians. This level of medical endorsement is a rarity for OTC appetite suppressants, making PhenQ the clear leader in the category. Main PhenQ Benefits & Features PhenQ delivers a multi-faceted approach to weight loss and appetite control. Here's what makes it the most effective appetite suppressant OTC and a top choice for weight management: 1. Clinically Proven Appetite Suppressant PhenQ's formula contains α-Lacys Reset®, a patented complex that accelerates metabolism and promotes thermogenesis, helping users suppress appetite and burn calories more efficiently. Clinical studies have shown that people using α-Lacys Reset® lost up to 7.24% of body fat, 3.44% of body weight, and gained 3.8% muscle mass, making it a unique weight loss supplement for those looking to lose weight while retaining lean muscle. 2. Reduces Food Cravings Through its blend of chromium picolinate, nopal cactus, and natural caffeine, PhenQ helps reduce cravings for sweets and carbs. This powerful appetite suppressant formula is designed to help users stay on track, avoid emotional eating, and break the cycle of late-night snacking. 3. Promotes Weight Loss and Fat Burning PhenQ combines thermogenic agents like Capsimax powder (a blend of capsicum, piperine, caffeine, and niacin) to ignite fat burning and help users reach their weight loss goals faster. This is not just an appetite suppressant, but a comprehensive weight loss supplement for total body transformation. 4. Enhances Energy and Mood Unlike many diet pills or prescription appetite suppressants that can cause fatigue or mood swings, PhenQ contains caffeine, nopal, and L-carnitine to provide all-day energy and cognitive support. This keeps users motivated, focused, and ready to conquer their health and fitness journey. 5. Supports Normal Appetite and Keto Lifestyles PhenQ is a natural appetite suppressant that fits perfectly into keto or low-carb diets, helping users manage appetite and maintain healthy eating habits for sustainable weight loss. 6. No Prescription Required—100% OTC As one of the strongest OTC appetite suppressants, PhenQ is available for purchase without a prescription. This makes appetite control more accessible than ever for millions of Americans. 7. Vegan & Vegetarian Friendly PhenQ is made from 100% vegan and vegetarian ingredients, ensuring inclusivity for a wide variety of dietary needs. Company Name and Location PhenQ (USA)Wolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United KingdomDistributed in the USA, Canada, UK, Australia and globally PhenQ Pricing Details PhenQ is competitively priced with attractive savings for multi-bottle purchases and includes a risk-free guarantee: 1 Bottle: $69.99 (Retail $79.99) — 1 Month Supply 2 Bottles + 1 Free: $139.99 (Retail $239.99) — 3 Month Supply (Most Popular) 3 Bottles + 2 Free: $209.99 (Retail $399.99) — 5 Month Supply (Best Value) Free Shipping: On all orders over $79.99 60-Day Money-Back Guarantee: Try it risk-free Order and see current offers at official PhenQ website Launch Date & Availability PhenQ is now available to buy OTC in the United States and ships to over 190 countries. Orders are processed and shipped within 24–48 hours from warehouses in the US, UK, and Germany. PhenQ is also now available for purchase worldwide, providing rapid delivery and discreet packaging. Scientific Data and Studies PhenQ's appetite suppressant formula is backed by clinical research: α-Lacys Reset®: Clinical trials published in peer-reviewed journals demonstrate significant reductions in body weight, body fat, and increased muscle mass compared to placebo. Capsimax Powder: Research in Bioscience Report highlights the ability of capsaicinoids to increase thermogenesis and potentially stop the formation of new fat cells. Chromium Picolinate: An eight-week Cornell University study showed chromium supplementation helps reduce carb cravings and supports healthy blood sugar levels. Caffeine: Multiple studies confirm caffeine's ability to suppress appetite, increase alertness, and boost metabolic rate. Nopal Cactus: Rich in fiber and amino acids, nopal helps manage appetite, increase satiety, and reduce fluid retention. References: Whiting S, Derbyshire E, Tiwari BK. (2012) Appetite Control. Zemel MB, Thompson W, Milstead A, et al. (2004) Obesity Research. Docherty JP, Sack DA, et al. (2005) Journal of Psychiatry Practice. Health & Safety Benefits PhenQ is designed as a safe, effective alternative to prescription appetite suppressants and weight loss drugs: All-Natural Appetite Suppressant: PhenQ includes only natural, high-grade ingredients with a strong safety record. No Major Side Effects: No prescription required, and hundreds of thousands of users have reported no significant adverse effects. Suitable for Long-Term Use: Can be used as long as needed for weight management, unlike some weight loss drugs that are only approved for short-term use. No Habit-Forming Ingredients: Unlike some prescription appetite suppressants, PhenQ is non-addictive and safe for ongoing use. Made in FDA & GMP Approved Facilities: All manufacturing is done under strict quality controls in the US and UK. Scientific Innovation of OTC Weight Loss Supplements What makes PhenQ a leader among OTC appetite suppressants and diet pills? Multi-Action Formula: Combines the strongest ingredients for appetite control, fat burning, energy, and mood—unlike most other weight loss supplements that target a single aspect. α-Lacys Reset®: A unique, trademarked, and scientifically validated ingredient at the heart of PhenQ's effectiveness. Synergy of Ingredients: Each component supports the others for a holistic approach to appetite suppression and weight management. Transparency: Full ingredient disclosure and clinical research citations—no hidden blends or proprietary secrets. OTC Diet Pills Market Disruption PhenQ is fundamentally disrupting the appetite suppressant and weight loss supplement industry: Medically Studied by 800 Professionals: PhenQ's 'clinicians' choice' status is nearly impossible to attain and sets a new bar for OTC appetite suppressant pills. Outperforms Prescription Appetite Suppressants: Without the need for a prescription or risk of high blood pressure and other side effects, PhenQ is safer and more accessible. Superior to Traditional Diet Pills: PhenQ's multi-pronged formula makes it more effective than many single-purpose appetite suppressant pills or dietary supplements. No Prescription, No Hassle: PhenQ brings prescription-level results to the OTC market—no waiting rooms, no doctor's approval necessary. Consumer Benefits Users of PhenQ enjoy a wide range of benefits—making it the strongest and most trusted OTC appetite suppressant available: Strongest Appetite Suppressant OTC: Clinically proven to suppress appetite, crush cravings, and help users lose weight effectively. Promotes Weight Loss: Helps reduce calorie intake, supports fat burning, and assists in lowering body weight and body mass index. Appetite Control and Satiety: Natural ingredients help users feel full, satisfied, and in control of their eating habits. Counter Appetite and Emotional Eating: Reduces stress-related snacking and helps break the cycle of emotional eating. Supports Healthy Weight Management: Sustained use assists in long-term maintenance of healthy weight, reducing the risk of regaining lost pounds. Safe for Most Adults: No major side effects, no habit-forming components, and suitable for both men and women. Fits Modern Lifestyles: Only two pills per day, no drastic diet changes required, and works with keto and other popular diets. Money-Back Guarantee: If you're not satisfied, get a full refund within 60 days—no questions asked. Quote from PhenQ Spokesperson 'PhenQ is the result of years of scientific research and clinical study. To be named a clinicians' choice by over 800 medical professionals is an extraordinary honor—and a testament to our commitment to safety, effectiveness, and transparency. As the strongest OTC appetite suppressant available today, PhenQ is helping people in the USA and around the world take control of their appetite, lose weight safely, and achieve lasting health.'— Kay Norris, Product Innovation, PhenQ Distribution Channels Direct-to-Consumer: Only available from the official site to guarantee authenticity and best pricing. Worldwide Shipping: To over 190 countries, with free shipping on orders over $79.99. Discreet Packaging: All orders shipped in plain packaging for your privacy. Website URL & Contact Person Details Website: Email: support@ Phone: +1 (646) 513 2632 For media inquiries:Wolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United Kingdomsupport@ Safety Certifications & Testing FDA & GMP Approved Facilities: Manufactured to the highest US and UK standards. Third-Party Lab Testing: For purity, potency, and safety. Full Ingredient Transparency: No hidden blends or undisclosed substances. Vegan & Vegetarian Safe: 100% plant-based ingredients. Product Usage & Dosage Recommended Use: Take one PhenQ pill with breakfast and one with lunch. Do Not Exceed Recommended Dose: Due to natural caffeine content, avoid taking after 3pm. Long-Term Use: Safe for ongoing appetite control and weight management. Appetite Suppressants in the Modern Age: How PhenQ Changes the Game Appetite suppressants work by helping users feel full, reduce food cravings, and lower overall calorie intake. However, most prescription appetite suppressants and weight loss drugs come with potential side effects, high blood pressure risks, and often require strict medical supervision. OTC appetite suppressants like PhenQ are changing this landscape by providing a safe, effective, and accessible solution for Americans struggling with weight management. PhenQ's unique composition of scientifically proven ingredients sets it apart from alli weight loss pill and other common dietary supplements. It is not just a diet pill; it is a comprehensive, medically endorsed appetite suppressant designed to suppress cravings, promote weight loss, and support lasting health. Conclusion: The Future of Appetite Control Is Here PhenQ is the strongest appetite suppressant over the counter now available in the USA and worldwide—backed by 800 medical professionals and trusted by nearly 200,000 satisfied customers. With its powerful, natural appetite suppressant formula, robust clinical validation, and unmatched safety profile, PhenQ is setting a new standard for OTC appetite suppressants and weight management. About PhenQ (USA) / Wolfson BrandsPhenQ is produced by Wolfson Brands, a global leader in health innovation. With a focus on science, safety, and customer success, PhenQ continues to redefine what's possible in appetite suppressant pills and weight loss supplements. Media Contact:Kay Norris, Head of Product InnovationWolfson Brands (UK) Limited12 Payne Street, Glasgow, G4 0LF, United Kingdomsupport@ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a physician before Phenq CONTACT: For media inquiries: Website: Email: support@ Phone: +1 (646) 513 2632 Wolfson Brands (UK) Limited 12 Payne Street, Glasgow, G4 0LF, United Kingdom support@ in to access your portfolio
Business Wire
an hour ago
- Business Wire
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced details of Embolden™, the Company's registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older. The Company has written agreement from the U.S. Food and Drug Administration (FDA) on key aspects of the registrational trial's design. 'We appreciate the partnership with the FDA as we aligned on the key elements of our NGN-401 registrational trial design, which will allow for rapid conversion of the current Phase 1/2 study to a pivotal trial,' said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We believe that the robust endpoint design, which was informed by key opinion leaders, caregiver input and primary market research with payors, will support NGN-401's best-in-class potential and provide key differentiating data critical to the Rett syndrome community and the future commercial success of NGN-401.' 'I appreciate the multi-domain approach across the clinical manifestations of Rett syndrome, and rigor in which the primary endpoint will be evaluated, including both the clinician perspective of improvement using the CGI-I scale with Rett syndrome anchors and videos to demonstrate gains of skills that are clinically meaningful for girls and women with Rett syndrome and their families,' said Elizabeth M. Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University, and principal investigator in the NGN-401 clinical trial. 'Participants treated with NGN-401 have demonstrated increased independence, with both fine and gross motor function improvement, and gained the ability to better communicate wants, needs and choices. I have been impressed with the improvements observed in participants after NGN-401 administration, which have included global improvement in signs and symptoms of Rett syndrome and gains of multi-domain developmental milestones that would not be expected to occur spontaneously in the post-regression stage of Rett syndrome. Evaluating treatment effect in participants ages 3 and above in the registrational study will provide important insights on the potential benefits of NGN-401 in younger patients early in the course of this progressive disease.' Obtained Written Agreement from FDA on the Following Key Elements of Embolden Registrational Trial Design After Discussions Under the START Program Study Design: Open-label, single arm, baseline control (i.e., participants serving as their own control); N=18 proposed, subject to feedback from the FDA. Patient Population: Females ages ≥ 3 years with Rett syndrome, which is consistent with Neurogene's analysis of the NIH-sponsored, International Rett Syndrome Foundation (IRSF) Rett syndrome natural history study that shows patients ages 3 and above rarely learn new skills/reach developmental milestones or relearn skills once lost. The FDA's written agreement endorsed the Company's analysis. Dose: 1E15 vector genomes (vg). Primary Endpoint: Responder-based composite endpoint that will assess an improvement in the Clinical Global Impression-Improvement (CGI-I) scale with Rett syndrome anchors and the gain of a developmental milestone/skill, compared to a participant's own baseline. Responders are defined as participants who: Attain a CGI-I score of ≤ 3 ('minimally improved'); and Gain any one developmental milestone/skill from a list of 28, as captured through standardized video recordings and independently verified by blinded central raters. Developmental milestones/skills were informed by a Rett syndrome caregiver survey, provided to the FDA, demonstrating that the acquisition of any single skill within the selected set is considered clinically meaningful. The primary endpoint will be evaluated at 12 months following NGN-401 administration, with feedback pending from the FDA to consider the addition of a 6-month endpoint. Neurogene has begun registrational trial initiation activities. 'It has been incredibly rewarding to see how RSRT's early investments in foundational Rett syndrome science helped lay the groundwork for what's now a promising gene therapy program approaching a registrational trial,' said Monica Coenraads, Founder and Chief Executive Officer of RSRT. 'RSRT has been a long-time champion of addressing the underlying genetic cause of Rett syndrome and Neurogene's program has the potential to do just that. We appreciate the thoughtful design of the trial that importantly incorporates the caregiver perspective on what meaningful improvement may look like. We congratulate the Neurogene team on reaching alignment with the FDA and thank the Rett community at large for their support in advancing this program. The future is bright!' 'Our partnership with Neurogene reflects a shared commitment to accelerating meaningful treatments for Rett syndrome,' said Laura Hameed, Chief Executive Officer of the International Rett Syndrome Foundation (IRSF). 'The use of IRSF's Natural History Study data to support the NGN-401 gene therapy registrational trial design is a powerful example of how families accelerate and streamline therapeutic development. We are grateful to the families that contributed to the NHS, and to the families participating in this trial whose time and commitment are essential to evaluating gene therapy for Rett syndrome.' Phase 1/2 Trial Data Support Registrational Trial Design Previously disclosed clinical data from the Phase 1/2 study* support the registrational trial design. Data showed improvements in Rett syndrome assessments with an aggregate of 23 developmental milestones/skills acquired in the first four participants. Specifically, the four participants: Each achieved a clinically meaningful rating of 2, or 'much improved,' on the CGI-I; and Collectively achieved 23 developmental milestones/skills in the core clinical domains of Rett syndrome – hand function/fine motor, communication/language, and ambulation/gross motor, including: Participant 1 gained 10 skills across multiple domains by 15 months post-dose; Participant 2 gained 8 skills across multiple domains by 12 months post-dose; Participant 3 gained 3 skills across multiple domains by 9 months post-dose; and Participant 4 gained 2 skills by 3 months post-dose. *Efficacy data from the first four participants; as of data cut-off date of October 17, 2024 Phase 1/2 Trial Enrollment and Update Neurogene previously shared that five additional participants had been dosed in the Phase 1/2 portion of the NGN-401 clinical trial during the first half of 2025. A total of 10 participants have received the 1E15 vg dose. There has been no evidence of hemophagocytic lymphohistiocytosis (HLH) / hyperinflammatory syndrome in any participant at the 1E15 vg dose level. Neurogene remains on track to share updated clinical efficacy and safety data in the second half of 2025. Cash Runway Update As of March 31, 2025, Neurogene had cash, cash equivalents, and investments of $292.6 million. The Company's current budget reflects a reallocation of capital from pipeline development to support pivotal trial activities for NGN-401. Neurogene now expects its existing resources will be sufficient to fund operations into early 2028. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial and the addition of a six month endpoint, and timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial; expected future interactions with or positions of the FDA; the safety, tolerability and efficacy of NGN-401; the potential for success of the Embolden registrational clinical trial for NGN-401 for the treatment of Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome; the effectiveness of the monitoring and treatment protocol for HLH in Neurogene's Phase 1/2 clinical trial of NGN-401; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things, uncertainties regarding interactions with and feedback received from the FDA staff responsible for approving the design of our registrational trial and the risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 24, 2025, Neurogene's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 9, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
